In-Person Access Only | 6.50 CE/CME Credits & MOC Points

Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $25 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com

The 3rd Annual NYC Pancreatic Cancer Consortium, held in New York City, will bring together leading experts across disciplines to address the growing clinical and scientific challenges in the management of pancreatic cancer. This symposium is dedicated to advancing a collaborative, multidisciplinary approach to pancreatic oncology, with a focus on improving outcomes through innovation, research, and team-based care.

This year’s program will feature speakers from Cold Spring Harbor, Columbia University Medical Center, Mount Sinai, Stony Brook University, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and NYU Langone, in addition to Northwell Health Cancer Institute.

Program Chairs:
Matthew Weiss, MD (Northwell Health Cancer Institute)
Danielle DePeralta, MD (Northwell Health Cancer Institute)
Dave Tuveson, MD (Cold Spring Harbor Laboratory)

Conference Agenda
Friday, November 13, 2026

7:30 AM
Breakfast and Exhibits

8:00 AM
Welcome & Introduction
Matthew Weiss, MD | Northwell Health Cancer Institute

8:15 AM - 9:00 AM
Non-CME Breakfast - Ipsen

9:00 - 9:35 AM
CASE BASED DISCUSSION I: UPDATES & CONTROVERSIES IN ROBOTIC PANCREAS SURGERY

• Robotic Pancreas Surgery: Innovative Techniques

• Future of AI integration

9:45 - 9:55 AM
Break and Exhibits

9:55 - 10:40 AM
CASE-BASED DISCUSSION II: LOCALLY ADVANCED PANCREATIC CANCER

• Management of Biliary and Duodenal Obstruction in Non-Surgical Patients

• Medical Oncology Talk

• Updates in Radiation Oncology

• Intra-Arterial Therapy for Locally Advanced Pancreatic Cancer

• Surgical Resection for Locally Advanced PDAC: Patient Selection and Long-Term Outcomes

10:40 - 11:10 AM
Networking Break

11:10 - 11:55 AM
CASE-BASED DISCUSSION III: METASTATIC PANCREATIC CANCER

• Therapeutic Development to Stop Pancreatic Cancer Metastasis

• Circulating Tumor DNA (ctDNA)

• Endoscopic Management of Complications in the Metastatic Patient

11:55 AM - 12:25 PM
KEYNOTE SPEAKER PRESENTATION - Pan-RAS Inhibitors

12:25 - 12:45 PM
Lunch and Exhibits

12:45 - 1:30 PM
Non-CME Lunch - Revolution Medicines

1:30 - 1:40 PM
Housekeeping & Survey

1:40 - 2:25 PM
PATIENT & CAREGIVER PERSPECTIVE (ACP SESSION): WHAT WE WISH WE KNEW EARLIER AND WHAT WE WISH OUR CLINICAL TEAM KNEW

• Patients and Advanced Practice Providers from each site will discuss challenges, victories, and lessons learned

2:25 - 3:10 PM
CASE-BASED DISCUSSION IV: PANCREATIC NEUROENDOCRINE TUMORS (PNET)

• Is There a Role for Endoscopic Ablation of Small PNET?

• Evolving Systemic Therapy for Advanced PNETs

• Shrinking the Boundaries: The Role of Surgery in Patients with Metastatic PNETs

• PRRT Update

3:10 - 3:55 PM
CASE-BASED DISCUSSION V: GENETIC / HEREDITARY HIGH-RISK PANCREATIC CANCER

• Lessons from Longitudinal Imaging: What Are We Missing During Surveillance?

• Is Screening Effective in High-Risk Patients?

• Patient Experience in a Surveillance Program: Does Screening Create Unnecessary Anxiety?

4:00 - 4:25 PM
Closing Remarks & Adjourn

4:30 PM
Networking Cocktail Reception

Agenda Subject To Change. All times are EST.

• Learning Objectives

  • Review and analyze advances in the multi-modality treatment of pancreatic cancer including newly available clinical trials.

  • Identify specific clinical trials available to pancreatic cancer patients at different stages of their disease process.

  • Describe specific molecular or genetic mutations found in pancreatic cancers that would indicate use of specific medications to treat the disease.

• Accreditation Information | 6.50

  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

  Nurses (ANCC) Credit Designation

  Amedco LLC designates this activity for a maximum of 6.5 ANCC contact hours.

  Physicians (ACCME) Credit Designation

  Amedco LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

  Amedco LLC designates this activity for a maximum of 6.5 knowledge-based CPE contact hours.

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program